Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MOBQ | Common Stock | Conversion of derivative security | $510K | +408K | +15.79% | $1.25 | 2.99M | Jun 30, 2022 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MOBQ | Notes | Conversion of derivative security | -510K | -100% | 0 | Jun 30, 2022 | Common Stock | 510K | $1.25 | Direct | F1, F2, F3, F4 | ||
transaction | MOBQ | Warrants | Conversion of derivative security | +204K | +16.48% | 1.44M | Jun 30, 2022 | Common Stock | 204K | $4.00 | Direct | F1, F2, F3, F5 |
Id | Content |
---|---|
F1 | The 2,992,354 common shares includes shares owned directly by Dr. Salkind, the doctor and his wife and through a trust in which Dr. Salkind is the trustee. The derivative securities listed in Table II are derivative securities owned directly by Dr. Salkind and his wife and by the trust. |
F2 | The board of directors of the issuer accepted Dr. Salkind's offer to convert $510,000 of convertible notes at a reduced conversion price of $1.25 per share into 408,000 common shares and warrants to purchase 204,000 shares at an exercise price of $4.00 per share through September 30, 2029. |
F3 | Not applicable. |
F4 | Left blank intentionally. |
F5 | 1,441,500 derivative securities include the following: (i) 390,625 common stock purchase warrants exercisable at $4.00 per share through September 2023; (ii) 10-year options to purchase 35,000 shares granted on December 8, 2021; and (iii) warrants to purchase 1,015,875 shares exercisable through September 30, 2029 which were issuable on June 30, 2022 as a result of the note conversion. |